CRP and coronary artery disorder: In the first clinical trial (LoDoCo), open-label use of low-dose colchicine (0.5 mg/day) reduced MACE in patients with stable coronary artery disease [hazard ratio 0.33, 95% confidence interval (CI) 0.18–0.59], regardless of baseline CRP levels, on top of optimal medical therapy, including antiplatelet drugs and statins (Table 1).10